For example, in the EF-14 trial that identified TTFields as a potential standard therapy for GBM, OS was 21.2 months in MGMT promoter-methylated patients who received TMZ and RT alone.4 Moreover, in the international study investigating dose-dense TMZ, among MGMT promoter-methylated patients receiving standard dose TMZ, OS and PFS were 21.4 and 6.5 months, respectively.18 Here, MGMT is linked to glioblastoma.